摘要
目的对安博维与依伦平治疗原发性高血压进行比较研究。方法将132例入选血压90 mm Hg(1 mm Hg=0.133 kPa)≤舒张压(DBP)<110 mm Hg,且收缩压(SBP)<180 mm Hg的来院治疗的患者分成两组,一组(n=62)加用安博维(厄贝沙坦)150 mg,每日1次;另一组(n=70)加用依伦平(厄贝沙坦150 mg+氢氯噻嗪12.5 mg)片,每日1次,观察8周,对两组血压、心率、血压达标率、降压有效率、不良反应进行比较。结果两组在分组后1周SBP、DBP和脉压(PP)均开始下降,依伦平组在分组后1周,安博维在分组后2周SBP、DBP和PP下降幅度较分组时差异有统计学意义(P<0.01);两组间SBP、DBP和PP在整个观察期内相比,同时间随访观察值、心率(HR)差异无统计学意义。结论安博维与依伦平在治疗原发性高血压方面的疗效、安全性和耐受性方面均较好,相比之下依伦平起效更快,降压有效率、达标率更高,是原发性高血压治疗的理想用药。
Objective To study the irbesartan and irbesartan/hydrochlorthiazide-regiment comparatively treating for primary hypertension.Methods One hundred and thirty-two patients whose blood pressure 90 mm Hg≤DBP〈110 mm Hg(1 mm Hg=0.133 kPa),and SBP180 mm Hg have been divided into two groups,one group(n=62) received irbesartan(150 mg/d),the other group(n=70) received irbesartan/hydrochlorothiazide regiment(150 mg irbesartan+12.5 mg hydrochlorothiazide regiment) per day,and all observed for 8 weeks,comparatively study index such as BP,HR,target achieving rate,depressurization effective power,adverse effect etc.Results After two groups have been treated with drug for one week,SBP,DBP and PP begin to descend,irbesartan/hydrochlorothiazide-regiment group on the first week,the descending extent of SBP,DBP and PP had significant difference after 2 weeks in irbesartan group(P〈0.01).During whole observation stage,the follow up observed number,HR of two groups had no significant difference.Conclusion The therapeutic effect,safety,survivability of irbesartan and irbeartan/hydrochlorothiazide-regiment treating for primary hypertension are good,irbeartan/hydrochlorothiazide-regiment play effect quickly,the effective power,target achieving rate of which is higher,so it can be used for lot medication in treating for primary hypertension.
出处
《临床医学》
CAS
2010年第1期12-13,共2页
Clinical Medicine
关键词
原发性高血压
安博维
依伦平
Primary hypertension
Irbesartan
Irbseartan/hydrochlorothiazide regiment